Several studies have shown that A20 is closely associated with the pathological processes involved in inflammatory and autoimmune diseases, including inflammatory bowel disease (Zhou et al., 2021), rheumatoid arthritis (Malynn and Ma, 2019), chronic inflammatory lung disease (Momtazi et al., 2019), multiple atherosclerotic disease (Perga et al., 2021), lupus nephritis (Sun et al., 2019), and atherosclerosis (Angolano et al., 2021), which is mostly related to that A20 can inhibit the NF-κB signaling pathway in a feedback manner. This evidence concerns the gene TNFAIP3 and inflammatory bowel disease.